

From: "Dualsystems Biotech" <pr@dualsystems.com>
Subject: Dualsystems Biotech announces collaboration with PTC Therapeutics
Date: 9. Mai 2011 16:34:49 MESZ
To: "" <info@cti-invest.ch>
Reply-To: "Dualsystems Biotech" <pr@dualsystems.com>

Dualsystems Biotech Press Release - For immediate distribution

Is this email not displaying correctly?
[View it in your browser.](#)



Dualsystems Biotech AG Press Release - For immediate distribution

Dualsystems Biotech announces drug profiling agreement with PTC Therapeutics

Zürich Switzerland – May 9, 2011 – Dualsystems Biotech today announced a drug profiling agreement with US-based PTC Therapeutics, Inc. Under the agreement, Dualsystems Biotech will use its drug profiling platform to identify molecular targets for an undisclosed small molecule candidate of PTC Therapeutics' development pipeline. *"As we expand our international client base with a strong focus on North America which presents significant business opportunities, we are particularly pleased to initiate a collaboration in the field of drug profiling with PTC Therapeutics"*, said Daniel Auerbach, CEO of Dualsystems Biotech. *"We are proud that PTC Therapeutics, a leading biotech company with cutting edge expertise in RNA biology and pioneering novel oral treatments of serious and life threatening diseases, has chosen Dualsystems Biotech as a partner to help uncover molecular targets for their key small molecule drug candidates."*

"We are impressed with the innovative screening technology that Dualsystems Biotech has developed over the last ten years" said Joseph Colacino, Ph.D., Vice President of Drug Discovery of PTC Therapeutics. *"Dualsystems' novel screening method has expanded the toolbox to study protein interactions important to the mechanism of action of small molecule drugs. We look forward to utilizing this exciting technology to gain an in depth understanding of the biological activity of key small molecules in our pipeline."*

About Dualsystems Biotech AG

Dualsystems Biotech is a CRO located in Zürich, Switzerland with a subsidiary in San Pedro, CA, USA serving the international research community in both academia and the pharmaceutical, biotech, agchem and cosmetic industries. Dualsystems Biotech's screening platforms enable the identification of small molecule-protein and protein-protein interactions in any cellular setting. Dualsystems Biotech's innovative drug profiling technologies have significant advantages in cost, speed and sensitivity compared to similar screening technologies for small molecules currently available. They are a powerful tool to accelerate drug discovery and development in the field of mode of action identification, drug re-positioning and off-target effect identification in key therapeutic areas, such as oncology and inflammation.

For more information, visit the company's website at www.dualsystems.com

Copyright © 2011 Dualsystems Biotech AG, All rights reserved.

You are receiving this email because you have a business relationship with Dualsystems Biotech, opted in at our website or consented to receive information about our activities.

Our mailing address is:
Dualsystems Biotech AG
Grabenstrasse 11a
Schlieren, - 8952

[Add us to your address book](#)

[unsubscribe from this list](#) | [update subscription preferences](#) | [view email in browser](#)

